Table 4. Associated Baseline Factors of Biochemical Progression-Free Survival via Univariable and Multivariable Analyses.
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | p value | HR | (95% CI) | p value | |
| Age | 1.009 | (0.968-1.052) | 0.680 | |||
| BMI | 0.938 | (0.831-1.059) | 0.302 | |||
| ECOG PS ≥1 | 1.042 | (0.572-1.898) | 0.893 | |||
| Gleason score | ||||||
| ≤8 | 1.356 | (0.697-2.638) | 0.370 | |||
| ≥9 | 0.738 | (0.379-1.436) | 0.370 | |||
| Clinical T stage | ||||||
| ≥T3 | 0.907 | (0.484-1.699) | 0.760 | |||
| T4 | 1.103 | (0.589-2.065) | 0.760 | |||
| Clinical N stage | ||||||
| N1 | 0.736 | (0.392-1.382) | 0.340 | |||
| PSA at diagnosis | 1.000 | (1.000-1.000) | 0.647 | |||
| PSA at CRPC diagnosis | 1.000 | (1.000-1.001) | 0.307 | |||
| Hb | 0.904 | (0.738-1.107) | 0.328 | |||
| NLR | 1.027 | (0.944-1.117) | 0.534 | |||
| Albumin | 1.732 | (0.797-3.765) | 0.165 | |||
| Prior radical prostatectomy | 0.728 | (0.355-1.494) | 0.387 | |||
| Prior palliative EBRT | 1.292 | (0.675-2.472) | 0.439 | |||
| DTX+ADT | 0.583 | (0.316-1.075) | 0.084 | |||
| Number of DTX cycles | 0.876 | (0.796-0.964) | 0.007 | 0.876 | (0.796-0.964) | 0.007 |
| Extent of disease | ||||||
| Bone metastasis | 0.855 | (0.303-2.414) | 0.767 | |||
| Lymph node metastasis | 1.087 | (0.563-2.096) | 0.804 | |||
| Lung or liver metastasis | 0.788 | (0.188-3.304) | 0.745 | |||
HR, hazard ratio; CI, confidence interval; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.